Insider Selling: Medpace Holdings

Trending News 🌥️

Medpace Holdings Stock Fair Value – Medpace Holdings ($NASDAQ:MEDP) is a contract research organization that provides clinical drug development services to the pharmaceutical and biotechnology industries. The company has been sold by an insider.

This could be a sign that the insider is worried about the company’s future prospects. Investors should do their own research before making any decisions about whether to buy or sell shares of Medpace Holdings.

Share Price

The company has been buoyed by strong earnings reports and positive analyst commentary. Despite the insider selling, Medpace Holdings stock remains a strong performer, and investors seem to remain bullish on the company’s prospects.

VI Analysis – Medpace Holdings Stock Fair Value Calculator

Investors generally believe that a company’s fundamentals reflect its long term potential. The intrinsic value of a stock is the present value of all future cash flows that the company is expected to generate. Many investors use a variety of methods to calculate the intrinsic value of a stock, but the most popular method is the discounted cash flow (DCF) method. The DCF method discounts all future cash flows that the company is expected to generate back to the present day. The discount rate that is used is the company’s weighted average cost of capital (WACC).

The WACC reflects the riskiness of the company’s cash flows and is composed of the cost of equity and the cost of debt. The intrinsic value of MEDPACE HOLDINGS share is around $208.0, calculated by VI Line. Now MEDPACE HOLDINGS stock is traded at $220.7, a fair price overvalued by 6%.

VI Peers

Medpace’s services include clinical trial management, data management, biostatistics, and medical writing. Medpace’s competitors include Icon PLC, Syneos Health Inc, and IQVIA Holdings Inc.

– Icon PLC ($NASDAQ:ICLR)

Icon PLC is a publicly traded company with a market capitalization of $14.59 billion as of March 2022. The company has a return on equity of 4.28%. Icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company has a network of over 80 sites in 40 countries. Icon’s services include clinical research, regulatory affairs, quality management, data management, and biostatistics.

– Syneos Health Inc ($NASDAQ:SYNH)

Synoes Health Inc is a pharmaceutical company with a market cap of 4.81B as of 2022. The company has a Return on Equity of 9.89%. The company develops, manufactures, and sells pharmaceutical products. The company’s products include prescription drugs, over-the-counter drugs, and medical devices. The company operates in the United States, Europe, and Asia.

– IQVIA Holdings Inc ($NYSE:IQV)

IQVIA Holdings Inc is a global healthcare company that provides market research, data, and analytics solutions to help customers drive healthcare transformation and growth. The company’s market cap as of 2022 is 33.49B, and its ROE is 19.29%. IQVIA’s customers include healthcare payers and providers, pharmaceutical and biotech companies, and government agencies. The company’s solutions help its customers drive healthcare transformation by improving patient outcomes, reducing costs, and increasing access to care.

Summary

Investing in MEDPACE HOLDINGS can be a great way to gain exposure to the healthcare sector. The company provides clinical research services to the pharmaceutical and biotechnology industries, and has a strong track record of success. The company’s share price has been on a tear in recent years, and it looks well-positioned to continue its growth trajectory. Given its strong fundamentals, MEDPACE HOLDINGS is a stock worth considering for any investor looking to add healthcare exposure to their portfolio.